Hawkins Richard J 4

What Happened
Richard J. Hawkins, a director of Plus Therapeutics (PSTV), received two restricted stock unit (RSU) awards on May 14, 2026 totaling 7,372 RSUs (3,686 + 3,686). The awards are recorded at $0.00 per unit (no cash exchanged) and are derivative awards that convert to common shares as they vest.

Key Details

• Transaction date: 2026-05-14; Form 4 filed 2026-05-18 (filed four days after the transaction). Form 4s are typically due within 2 business days, so this filing appears later than usual.
• Award type: RSUs (derivative), 3,686 RSUs reported twice = 7,372 RSUs total. Price: $0.00 per RSU; total immediate value reported: $0.
• Vesting (Footnote F1): Each RSU represents a contingent right to one share. Vesting is ratable over four quarters, with 1/4 vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
• Additional footnote (F2): The filing also includes language about option vesting (monthly over 12 months and full vesting at the 2027 Annual Meeting); this pertains to other award terms disclosed in the filing.
• Shares owned after transaction: Not specified in the reported data.

Context
RSU grants are compensation awards that convert into shares as they vest; they are not open-market purchases or sales. Such awards are routine director compensation and do not, by themselves, indicate insider buying or selling sentiment.